View all recent publications

Joseph Mikhael

MD

Mayo Clinic

Dr. Mikhael’s predominant research interest is in multiple myeloma and its related conditions: Waldenstrom’s macroglobulinemia and amyloidosis. He also does research in medical education, benign hematology and pharmacoeconomics:

Multiple myeloma, Waldenstrom’s and amyloidosis: He is the principal investigator of multiple clinical trials in both newly diagnosed and relapsed disease. He is also interested in the field of quality-of-life in multiple myeloma patients.
Medical education: Dr Mikhael is interested in various innovative methods of medical education.
Benign hematology: He is involved in research in agents for thrombosis. He also is involved in ITP research.
Pharmacoeconomics: He develops models to account for the cost of cancer care and validates therapies based upon their cost-effectiveness.

EHA 2017 | Social media – a useful tool for hematological research

EHA 2017 | Venetoclax as a potential treatment for MM with t(11;14)

EHA 2017 | Isatuximab and pomalidomide for the treatment of MM

ASH 2016 | Marginalized and high-risk multiple myeloma patients: how to address this issue

ASH 2016 | Developments in multiple myeloma – immunotherapy and personalized medicine

ASH 2016 | The potential of tweet chats

ASH 2016 | The benefits of video on social media

ASH 2016 | Why research institutes should use social media

ASH 2016 | The use of social media to reach out to patients and help improve clinical trials

ASCO 2016 | Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors

ASCO 2016 | Embracing the use of social media at medical congresses

ASH 2015 | Where do new drugs fit into the treatment landscape of multiple myeloma?

ASH 2015 | The Phase II clinical trial of ixazumib, the first oral proteasome inhibitor in MM

ASH 2015 | Social Media for the Hematologist by Dr Joseph Mikhael

ASH 2015 | Overview of a Phase II clinical trial of isatuximab

ASCO 2015 | Results of the phase 2 trial of daratumumab in multiple myeloma

1
2
Next